IQVIA presents: Mastering Real World Evidence across the product lifecycle, an imperative for Biopharma

Real world evidence is increasingly accepted by regulators and payers and has shown tremendous potential when applied systematically and strategically along the pharmaceutical value chain, becoming an imperative rather than just an opportunity. It has the power to maximise clinical development, drive investors discussions, meet regulator demands and adapt to payer evidence needs. Importantly for Biotech companies, early planning for use of Real World Evidence has proven beneficial and cost-effective. For example, it can improve clinical trial planning and helps understand patient profiles and characterize the unmet need with a natural history study in the early clinical development stages. It can provide context in single arm trials for rare patient populations by leveraging real world data as a comparator arm or even confirm risk-benefit ratio of the product pre- and post-marketing approval by optimizing your target product profile.

To learn more about the  power of Real World Evidence for biotechs and how IQVIA can support your evidence strategy, please join us on 18^th of October at 4 pm in the Auditorium of the Bio-Technopark.

You can register on this link: https://www.events.iqvia.com/NQ8dmM